Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy

International Network on Cancer, Infertility and Pregnancy

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Safety of sentinel lymph node (SLN) biopsy for breast cancer during pregnancy is insufficiently explored. We investigated efficacy and local recurrence rate in a large series of pregnant patients.

PATIENTS AND METHODS: Women diagnosed with breast cancer who underwent SLN biopsy during pregnancy were identified from the International Network on Cancer, Infertility and Pregnancy, the German Breast Group, and the Cancer and Pregnancy Registry. Chart review was performed to record technique and outcome of SLN biopsy, locoregional and distant recurrence, and survival.

RESULTS: We identified 145 women with clinically N0 disease who underwent SLN during pregnancy. The SLN detection techniques were as follows: 99mTc-labeled albumin nanocolloid only (n = 96; 66.2%), blue dye only (n = 14; 9.7%), combined technique (n = 15; 10.3%), or unknown (n = 20; 13.8%). Mapping was unsuccessful in one patient (0.7%) and she underwent an axillary lymph node dissection (ALND). Mean number of SLNs was 3.2 (interquartile range 1-3; missing n = 15). Positive SLNs were found in 43 (29.7%) patients and 34 subsequently underwent ALND. After a median follow-up of 48 months (range 1-177), 123 (84.8%) patients were alive and free of disease. Eleven patients experienced a locoregional relapse, including 1 isolated ipsilateral axillary recurrence (0.7%). Eleven (7.6%) patients developed distant metastases, of whom 9 (6.2%) died of breast cancer. No neonatal adverse events related to SLN procedure during pregnancy were reported.

CONCLUSIONS: SLN biopsy during pregnancy has a comparably low axillary recurrence rate as in nonpregnant women. Therefore, this method can be considered during pregnancy instead of standard ALND for early-stage, clinically node-negative breast cancer.

Original languageEnglish
Pages (from-to)551-557
Number of pages7
JournalBreast Cancer Research and Treatment
Volume168
Issue number2
DOIs
Publication statusPublished - Apr 2018

Fingerprint

Sentinel Lymph Node Biopsy
Breast Neoplasms
Safety
Pregnancy
Recurrence
Lymph Node Excision
Infertility
Registries
Albumins
Coloring Agents
Neoplasm Metastasis
Survival

Cite this

Axillary staging for breast cancer during pregnancy : feasibility and safety of sentinel lymph node biopsy. / International Network on Cancer, Infertility and Pregnancy.

In: Breast Cancer Research and Treatment, Vol. 168, No. 2, 04.2018, p. 551-557.

Research output: Contribution to journalArticle

International Network on Cancer, Infertility and Pregnancy. / Axillary staging for breast cancer during pregnancy : feasibility and safety of sentinel lymph node biopsy. In: Breast Cancer Research and Treatment. 2018 ; Vol. 168, No. 2. pp. 551-557.
@article{4aacaf15b12748c0acf5dd3e2fe021c5,
title = "Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy",
abstract = "BACKGROUND: Safety of sentinel lymph node (SLN) biopsy for breast cancer during pregnancy is insufficiently explored. We investigated efficacy and local recurrence rate in a large series of pregnant patients.PATIENTS AND METHODS: Women diagnosed with breast cancer who underwent SLN biopsy during pregnancy were identified from the International Network on Cancer, Infertility and Pregnancy, the German Breast Group, and the Cancer and Pregnancy Registry. Chart review was performed to record technique and outcome of SLN biopsy, locoregional and distant recurrence, and survival.RESULTS: We identified 145 women with clinically N0 disease who underwent SLN during pregnancy. The SLN detection techniques were as follows: 99mTc-labeled albumin nanocolloid only (n = 96; 66.2{\%}), blue dye only (n = 14; 9.7{\%}), combined technique (n = 15; 10.3{\%}), or unknown (n = 20; 13.8{\%}). Mapping was unsuccessful in one patient (0.7{\%}) and she underwent an axillary lymph node dissection (ALND). Mean number of SLNs was 3.2 (interquartile range 1-3; missing n = 15). Positive SLNs were found in 43 (29.7{\%}) patients and 34 subsequently underwent ALND. After a median follow-up of 48 months (range 1-177), 123 (84.8{\%}) patients were alive and free of disease. Eleven patients experienced a locoregional relapse, including 1 isolated ipsilateral axillary recurrence (0.7{\%}). Eleven (7.6{\%}) patients developed distant metastases, of whom 9 (6.2{\%}) died of breast cancer. No neonatal adverse events related to SLN procedure during pregnancy were reported.CONCLUSIONS: SLN biopsy during pregnancy has a comparably low axillary recurrence rate as in nonpregnant women. Therefore, this method can be considered during pregnancy instead of standard ALND for early-stage, clinically node-negative breast cancer.",
author = "{International Network on Cancer, Infertility and Pregnancy} and Han, {S N} and F Amant and Cardonick, {E H} and S Loibl and Peccatori, {F A} and O Gheysens and Sangalli, {C A} and V Nekljudova and Steffensen, {K Dahl} and {Mhallem Gziri}, M and Schr{\"o}der, {C P} and Lok, {C A R} and A Verest and P Neven and A Smeets and G Pruneri and M Cremonesi and O Gentilini",
year = "2018",
month = "4",
doi = "10.1007/s10549-017-4611-z",
language = "English",
volume = "168",
pages = "551--557",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "2",

}

TY - JOUR

T1 - Axillary staging for breast cancer during pregnancy

T2 - feasibility and safety of sentinel lymph node biopsy

AU - International Network on Cancer, Infertility and Pregnancy

AU - Han, S N

AU - Amant, F

AU - Cardonick, E H

AU - Loibl, S

AU - Peccatori, F A

AU - Gheysens, O

AU - Sangalli, C A

AU - Nekljudova, V

AU - Steffensen, K Dahl

AU - Mhallem Gziri, M

AU - Schröder, C P

AU - Lok, C A R

AU - Verest, A

AU - Neven, P

AU - Smeets, A

AU - Pruneri, G

AU - Cremonesi, M

AU - Gentilini, O

PY - 2018/4

Y1 - 2018/4

N2 - BACKGROUND: Safety of sentinel lymph node (SLN) biopsy for breast cancer during pregnancy is insufficiently explored. We investigated efficacy and local recurrence rate in a large series of pregnant patients.PATIENTS AND METHODS: Women diagnosed with breast cancer who underwent SLN biopsy during pregnancy were identified from the International Network on Cancer, Infertility and Pregnancy, the German Breast Group, and the Cancer and Pregnancy Registry. Chart review was performed to record technique and outcome of SLN biopsy, locoregional and distant recurrence, and survival.RESULTS: We identified 145 women with clinically N0 disease who underwent SLN during pregnancy. The SLN detection techniques were as follows: 99mTc-labeled albumin nanocolloid only (n = 96; 66.2%), blue dye only (n = 14; 9.7%), combined technique (n = 15; 10.3%), or unknown (n = 20; 13.8%). Mapping was unsuccessful in one patient (0.7%) and she underwent an axillary lymph node dissection (ALND). Mean number of SLNs was 3.2 (interquartile range 1-3; missing n = 15). Positive SLNs were found in 43 (29.7%) patients and 34 subsequently underwent ALND. After a median follow-up of 48 months (range 1-177), 123 (84.8%) patients were alive and free of disease. Eleven patients experienced a locoregional relapse, including 1 isolated ipsilateral axillary recurrence (0.7%). Eleven (7.6%) patients developed distant metastases, of whom 9 (6.2%) died of breast cancer. No neonatal adverse events related to SLN procedure during pregnancy were reported.CONCLUSIONS: SLN biopsy during pregnancy has a comparably low axillary recurrence rate as in nonpregnant women. Therefore, this method can be considered during pregnancy instead of standard ALND for early-stage, clinically node-negative breast cancer.

AB - BACKGROUND: Safety of sentinel lymph node (SLN) biopsy for breast cancer during pregnancy is insufficiently explored. We investigated efficacy and local recurrence rate in a large series of pregnant patients.PATIENTS AND METHODS: Women diagnosed with breast cancer who underwent SLN biopsy during pregnancy were identified from the International Network on Cancer, Infertility and Pregnancy, the German Breast Group, and the Cancer and Pregnancy Registry. Chart review was performed to record technique and outcome of SLN biopsy, locoregional and distant recurrence, and survival.RESULTS: We identified 145 women with clinically N0 disease who underwent SLN during pregnancy. The SLN detection techniques were as follows: 99mTc-labeled albumin nanocolloid only (n = 96; 66.2%), blue dye only (n = 14; 9.7%), combined technique (n = 15; 10.3%), or unknown (n = 20; 13.8%). Mapping was unsuccessful in one patient (0.7%) and she underwent an axillary lymph node dissection (ALND). Mean number of SLNs was 3.2 (interquartile range 1-3; missing n = 15). Positive SLNs were found in 43 (29.7%) patients and 34 subsequently underwent ALND. After a median follow-up of 48 months (range 1-177), 123 (84.8%) patients were alive and free of disease. Eleven patients experienced a locoregional relapse, including 1 isolated ipsilateral axillary recurrence (0.7%). Eleven (7.6%) patients developed distant metastases, of whom 9 (6.2%) died of breast cancer. No neonatal adverse events related to SLN procedure during pregnancy were reported.CONCLUSIONS: SLN biopsy during pregnancy has a comparably low axillary recurrence rate as in nonpregnant women. Therefore, this method can be considered during pregnancy instead of standard ALND for early-stage, clinically node-negative breast cancer.

U2 - 10.1007/s10549-017-4611-z

DO - 10.1007/s10549-017-4611-z

M3 - Article

C2 - 29235045

VL - 168

SP - 551

EP - 557

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -